Science News
from research organizations
Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity
- Date:
- April 2, 2011
- Source:
- American Association for Cancer Research
- Summary:
- The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to new data.
- Share:
FULL STORY
Story Source:
Materials provided by American Association for Cancer Research. Note: Content may be edited for style and length.
Cite This Page:
American Association for Cancer Research. "Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity." ScienceDaily. ScienceDaily, 2 April 2011. <www.sciencedaily.com
American Association for Cancer Research. (2011, April 2). Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity. ScienceDaily. Retrieved July 26, 2024 from www.sciencedaily.com
American Association for Cancer Research. "Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity." ScienceDaily. www.sciencedaily.com
Explore More
from ScienceDaily
RELATED STORIES